Trial Profile
Changes in overactive bladder symptoms after withdrawl of solifenacin following initial 12-week combination therapy with tamsulosin: A multicenter prospective study in men with benign prostatic hyperplasia and coexisting overactive bladder
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 02 Sep 2016
Price :
$35
*
At a glance
- Drugs Solifenacin (Primary) ; Tamsulosin
- Indications Benign prostatic hyperplasia; Overactive bladder
- Focus Therapeutic Use
- Sponsors Astellas Pharma
- 19 Apr 2012 New trial record